Cargando…

Association of Community Water Lead Levels and Erythropoietin Stimulating Agent Use among End-Stage Kidney Disease Patients

Detalles Bibliográficos
Autores principales:	Danziger, John, Dodge, Laura E., Mukamal, Kenneth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Environmental Health Perspectives 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770039/ https://www.ncbi.nlm.nih.gov/pubmed/36542478 http://dx.doi.org/10.1289/EHP10815

Ejemplares similares

Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure
por: Pieringer, Herwig, et al.
Publicado: (2008)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatment
por: Zumrutdal, Aysegul
Publicado: (2010)

Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease
por: Khankin, Eliyahu V., et al.
Publicado: (2010)

Effect of erythropoietin-stimulating agent on uremic inflammation
por: Tanaka, Yuri, et al.
Publicado: (2012)

Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: Is it feasible?
por: Gabutti, Luca, et al.
Publicado: (2011)

Malnutrition and Erythropoietin Resistance among Patients with End-Stage Kidney Disease: Where Is the Perpetrator of Disaster?
por: Feret, Wiktoria, et al.
Publicado: (2022)

Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease
por: Panjeta, Mirsad, et al.
Publicado: (2017)

“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
por: Ashraf, Bilal, et al.
Publicado: (2021)

Effect of Periodic Transfusion on Erythropoietin Concentration in End Stage Renal Disease
por: Hong, Sae Yong, et al.
Publicado: (1992)

Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease
por: Beach, Lauren B., et al.
Publicado: (2016)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients
por: Bae, Myoung Nam, et al.
Publicado: (2015)

Saphenous Vein Graft Disease and Serum Erythropoietin Level
por: Joob, Beuy, et al.
Publicado: (2016)

Erythropoietin and renal protection
por: Baradaran, Azar, et al.
Publicado: (2013)

Polymorphisms of the ELANE Gene Promoter Region in End-Stage Chronic Kidney Disease Patients
por: Fernandes, Rafael, et al.
Publicado: (2016)

Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study
por: Huang, Yu‐Shan, et al.
Publicado: (2022)

Heritability and association with distinct genetic loci of erythropoietin levels in the general population
por: Corre, Tanguy, et al.
Publicado: (2021)

Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients
por: Nasri, Hamid
Publicado: (2014)

Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients
por: Hanudel, Mark R., et al.
Publicado: (2019)

The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions
por: Palazzuoli, Alberto, et al.
Publicado: (2014)

Erythropoietin: a multimodal neuroprotective agent
por: Byts, Nadiya, et al.
Publicado: (2009)

Baseline Soluble Anti-erythropoietin Antibody Level Is an Independent Associated Factor for Follow-Up Erythropoietin Demand in Maintenance Dialysis Patients With End-Stage Renal Disease: A Prospective Cohort Study
por: Zhang, Ying, et al.
Publicado: (2020)

European nephrologists’ views on remote patient management for end-stage kidney disease
por: de Jong, Rianne W, et al.
Publicado: (2021)

Disparities in the Timing of Preoperative Hemodialysis Among Patients With End-Stage Kidney Disease
por: Fielding-Singh, Vikram, et al.
Publicado: (2023)

Renal failure in the intensive care unit: acute kidney injury compared to end-stage renal failure
por: Ostermann, Marlies, et al.
Publicado: (2008)

Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
por: Inrig, Jula K, et al.
Publicado: (2011)

Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice
por: Gaipov, Abduzhappar, et al.
Publicado: (2020)

Hyperproduction of erythropoietin in nonanemic lead-exposed children.
por: Factor-Litvak, P, et al.
Publicado: (1998)

Agents Influencing the Production and Action of Erythropoietin in Man
por: Jepson, J. H.
Publicado: (1968)

Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011)

Comparison of the acute erythropoietic capacities of erythropoietin and U-74389G in terms of hemoglobin levels
por: Tsompos, Constantinos, et al.
Publicado: (2017)

A Pilot Randomized Trial of Intradialysis Yoga for Patients With End-Stage Kidney Disease
por: Herron, Ann, et al.
Publicado: (2022)

V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients
por: Wong, Henry Sung-Ching, et al.
Publicado: (2017)

Lack of association between erythropoietin treatment and risk of depression in patients with end-stage kidney disease on maintenance dialysis: a nationwide database study in Taiwan
por: Lin, Pao-Yen, et al.
Publicado: (2021)

Low serum PSA levels of diabetes mellitus-caused end-stage renal disease patients
por: Wada, Yoshihiro, et al.
Publicado: (2008)

Idiopathic Oxalate Nephropathy Leading to End-Stage Kidney Disease: A Case Report
por: Saleem, Maryam, et al.
Publicado: (2023)

An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients
por: Sonia, Shamsun Nahar, et al.
Publicado: (2023)

Queries Regarding Local Erythropoietin Injection in Tibiofibular Fracture Healing
por: Rölfing, Jan Hendrik Duedal, et al.
Publicado: (2013)

Erythropoietin Stimulates GABAergic Maturation in the Mouse Hippocampus
por: Khalid, Kasifa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5b6u3lth6gkrcavjdu9a4iapb0